Collagen is a protein found in skin, hair, nails, tendons, cartilage, and bones.

Our bodies naturally produce collagen using the foods we eat. But, in recent years, collagen peptides have gained popularity as a supplement to support joint, hair, skin, and gut health.

A new study led by Jennifer Fields, assistant professor of nutritional sciences in the College of Agriculture, Health and Natural Resources (CAHNR), provides evidence in favor of yet another application for collagen peptides – protecting female runners’ bones.

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from the University Hospital of Bonn (UKB), the Universities of Bonn, Basel, Toronto, and Yale, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut. This study has now been published in the journal Science Translational Medicine.

Scientists at the Icahn School of Medicine at Mount Sinai have uncovered the first high-resolution structure of NBCn2, a brain protein linked to epilepsy, autism spectrum disorder, and other neurological conditions, and developed the first compounds capable of inhibiting its activity. The findings provide a new framework for studying how altered brain signaling contributes to disease and may help advance future therapeutic research. Their findings were published today by Nature Communications [DOI:10.1038/S41467-026-75444-4].